NewAmsterdam Pharma
NAMS
18.41
-1.10
-5.64%
NewAmsterdam Pharma
US · NAMS
#2583 by market cap
Listed 1970
18.41
-1.10
-5.64%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Stifel Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/11/10
-
Rating change
A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $58Market Newswire · 2026/8/6
-
Company notice
NamSys Inc: MD&A - ENGLISHSEDAR · 2023/3/30
-
Company notice
NamSys Inc: MD&A - ENGLISHSEDAR · 2023/6/29
-
Rating change
Citi Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/10/15
-
Company notice
NamSys Inc: MD&A - ENGLISHSEDAR · 2022/9/28
-
Company notice
NamSys Inc: MD&A - ENGLISHSEDAR · 2022/6/29
-
Rating change
William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy RatingMarket Newswire · 2026/9/18
-
BMO Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $58Market Newswire · 2026/11/5
-
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/11/9
-
Rating change
Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/8/8
-
Cantor Fitzgerald Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $61Market Newswire · 2026/11/11
-
Company notice
NamSys Inc: MD&A - ENGLISHSEDAR · 2023/2/25
-
Rating change
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Cuts Target Price to $42Market Newswire · 2026/10/5
-
Rating change
Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $57Market Newswire · 2026/9/22
-
Rating change
Wells Fargo Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/11/5
-
Rating change
Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy RatingMarket Newswire · 2026/9/8
-
H.C. Wainwright Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $52Market Newswire · 2026/11/6
-
Rating change
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/11/5
-
Rating change
A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $52Market Newswire · 2026/8/7
-
Rating change
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $51Market Newswire · 2026/6/30
-
Rating change
Guggenheim Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/5/8
-
BMO Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $58Market Newswire · 2026/9/22
-
Rating change
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/8/4
-
Rating change
Stifel Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/9/8
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
NewAmsterdam Pharma discussion 0 comments